A biomarker can be a substance or structure measured in body parts, fluids or products that
can affect or predict disease incidence. As age-related macular degeneration (AMD) is the …

Choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) is an
important cause of visual morbidity globally. Modern treatment strategies for neovascular …

Oxidative damage to retinal pigment epithelial (RPE) has been identified as one of the major
regulatory factors in the pathogenesis of age-related macular degeneration (AMD). Catalpol …

Purpose We sought to determine if specific genetic single nucleotide polymorphisms (SNPs)
influence vascular endothelial growth factor inhibition response to ranibizumab in …

Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss
in the elderly. The gold standard of nAMD treatment is intravitreal injections of vascular …

Purpose The recent introduction of anti-VEGF drugs has widely changed the prognosis of
exudative age-related macular degeneration (AMD), even if a variable percentage of …

Our study assesses the effects of anti-VEGF (Vascular Endothelial Growth Factor) drugs and
Trichostatin A (TSA), an inhibitor of histone deacetylase (HDAC) activity, on cultured ARPE …

Background Anti-angiogenesis treatments are the most commonly used treatments for the
vision loss caused by exudative age-related macular degeneration (AMD), in which the anti …

Background The association of HTRA1 rs11200638 and ARMS2 rs10490924 gene
polymorphisms with response to intravitreal ranibizumab therapy among neovascular AMD …

Age-related macular degeneration (AMD) is a complex disease with multiple genetic and
environmental risk factors. In the age of molecular genetics, many investigators have …